Biomedical Catalyst – Staphylococcus aureus Vaccine

生物医学催化剂—金黄色葡萄球菌疫苗

• 批准号: MC_PC_14090
• 负责人: Simon J. Foster
• 金额: $ 58.71万
• 依托单位: University of Sheffield
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2013
• 资助国家: 英国
• 起止时间: 2013 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=MC_PC_14090
• 关键词: Biomedical; Catalyst; Staphylococcus; aureus; Vaccine

S. aureus is a bacterium that colonises the nasal lining and skin of >30% of people. Accidents, surgery or device implantation that breach natural barriers, allow invasion, which may result in life-threatening infections such as pneumonia and blood-borne infections particularly by the antibiotic resistant form (MRSA). Despite several attempts S. aureus no vaccine is yet available. All vaccine clinical trials have failed despite promising pre-clinical animal model data. The partners and subcontractors in this project led by Absynth Biologics Limited and the University of Sheffield are bringing together capabilities to address this problem namely: novel vaccine targets and technologies to more effectively stimulate the human immune system. This coupled with a greater understanding of the development of infection (physiological and immunological) will be used innovatively to select the best candidate vaccine for clinical development.

S.金黄色葡萄球菌是一种细菌，其在>30%的人的鼻粘膜和皮肤上定殖。意外事故、手术或器械植入会破坏自然屏障，导致侵入，这可能导致危及生命的感染，如肺炎和血液传播感染，特别是抗生素耐药形式（MRSA）。尽管有几次尝试，S。金黄色葡萄球菌尚无疫苗可用。尽管临床前动物模型数据很有希望，但所有疫苗临床试验都失败了。由Absynth Biologics Limited和谢菲尔德大学领导的该项目的合作伙伴和分包商正在汇集解决这一问题的能力，即：新的疫苗靶点和技术，以更有效地刺激人类免疫系统。再加上对感染发展（生理学和免疫学）的更深入了解，将创新地用于选择临床开发的最佳候选疫苗。